Subthalamic beta oscillations correlate with dopaminergic degeneration in experimental parkinsonism.


Journal

Experimental neurology
ISSN: 1090-2430
Titre abrégé: Exp Neurol
Pays: United States
ID NLM: 0370712

Informations de publication

Date de publication:
01 2021
Historique:
received: 23 07 2020
revised: 06 10 2020
accepted: 20 10 2020
pubmed: 6 11 2020
medline: 20 4 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

Excessive beta activity has been shown in local field potential recordings from the cortico-basal ganglia loop of Parkinson's disease patients and in its various animal models. Recent evidence suggests that enhanced beta oscillations may play a central role in the pathophysiology of the disorder and that beta activity may be directly linked to the motor impairment. However, the temporal evolution of exaggerated beta oscillations during the ongoing dopaminergic neurodegeneration and its relation to the motor impairment and histological changes are still unknown. We investigated motor behavioral, in-vivo electrophysiological (subthalamic nucleus, motor cortex) and histological changes (striatum, substantia nigra compacta) 2, 5, 10 and 20-30 days after a 6-hydroxydopamine injection into the medial forebrain bundle in Wistar rats. We found strong correlations between subthalamic beta power and motor impairment. No correlation was found for beta power in the primary motor cortex. Only subthalamic but not cortical beta power was strongly correlated with the histological markers of the dopaminergic neurodegeneration. Significantly increased subthalamic beta oscillations could be detected before this increase was found in primary motor cortex. At the latest observation time point, a significantly higher percentage of long beta bursts was found. Our study is the first to show a strong relation between subthalamic beta power and the dopaminergic neurodegeneration. Thus, we provide additional evidence for an important pathophysiological role of subthalamic beta oscillations and prolonged beta bursts in Parkinson's disease.

Identifiants

pubmed: 33148526
pii: S0014-4886(20)30344-7
doi: 10.1016/j.expneurol.2020.113513
pii:
doi:

Substances chimiques

Hydroxydopamines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113513

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Jens K Haumesser (JK)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.

Maximilian H Beck (MH)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.

Franziska Pellegrini (F)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.

Johanna Kühn (J)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.

Wolf-Julian Neumann (WJ)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.

Jennifer Altschüler (J)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.

Daniel Harnack (D)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany; Department of Neurologic Rehabilitation, Kliniken Beelitz, Beelitz-Heilstätten, Germany.

Andreas Kupsch (A)

Clinic of Neurology and Stereotactic Neurosurgery, Otto von Guericke University, Magdeburg, Germany.

Vadim V Nikulin (VV)

Department of Neurology, Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.

Andrea A Kühn (AA)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE), Germany.

Christoph van Riesen (C)

Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE), Germany; Berlin Institute of Health (BIH), Berlin, Germany; Department of Neurology, University Medicine Göttingen, Göttingen, Germany. Electronic address: christoph.van-riesen@med.uni-goettingen.de.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH